Richard S. Stack, M.D., SyneCor
William N. Starling, SyneCor
Ron Dollens, Guidant Corporation
David Douglass, Delphi Ventures
Nathan Every, M.D., Frazier Healthcare
Charles Goldstein, Ph.D., Becton Dickinson
William Knopf, M.D., Atlanta Cardiology Group
Michael Cohen, Deutsche Bank Alex. Brown
Robert Taber, Ph.D., Duke University

Richard S. Stack, M.D., SyneCor
William N. Starling, SyneCor
David Douglass, Delphi Ventures
Nathan Every, M.D., Frazier Healthcare
Louis Lange, Ph.D., M.D., CEO, CV Therapeutics, Inc.
Ray Larkin, former CEO, Nellcor, Inc.

Richard S. Stack, M.D.:

Richard S. Stack is Managing General Partner of SyneCor, LLC, a business generator of new Life Sciences companies based in the Research Triangle Park, North Carolina, and Menlo Park, California. SyneCor has significant academic, scientific, physician, venture capital, corporate, and investment banking partnerships and is focusing its efforts on the identification and development of proprietary, transformational technologies with extraordinary market potential in the cardiovascular disease field.

Dr. Stack is currently the Executive Director of ACRI (the Atlanta Cardiovascular Research Institute) and is a Professor of Medicine in Cardiology on leave of absence from Duke University Medical Center in Durham, North Carolina.

Dr. Stack completed his fellowship training in Cardiology at Duke University in 1982.

Dr. Stack's academic appointments have been served at Duke University Medical Center, beginning as an Associate in Medicine, Cardiology (1982-1983). Dr. Stack became an Assistant Professor of Medicine, Cardiology (1983-1989), and Associate Professor of Medicine, Cardiology (1989-1997), and is currently Professor of Medicine (Tenured - on leave of absence), Cardiology (1997 - present).

Dr. Stack has authored well over 330 manuscripts, book chapters, and abstracts. Dr. Stack has been a Principal and Co-principal Investigator for three NIH grants, has received multiple research awards during his career including International Award for Best Experimental Research (1995 - Thoraxcenter, Netherlands) and is listed in Who's Who in Cardiology.

Dr. Stack is also an inventor of several devices that are designed to improve and further the technology of angioplasty. Dr. Stack holds twelve current worldwide patents and has an additional eight patents pending on a variety of vascular and therapeutic devices. Currently, Dr. Stack's research team is developing a drug delivery stent device, invented by Dr. Stack, which holds great promise for overcoming many of the limitations of current stents. A major thrust of Dr. Stack's current basic and clinical research effort includes new devices for the treatment of peripheral vascular disease, particularly cerebrovascular disease.

top

William N. Starling:

William N. Starling is Chief Executive Officer of Synecor, LLC, (Synecor) a business generator of new Life Science companies based in Research Triangle Park (RTP), North Carolina, Santa Rosa, California, and Portola Valley, California. Synecor (www.synecor.com) has significant academic, scientific, physician, venture capital, corporate, and investment banking partnerships and is focusing its efforts on the identification and development of proprietary, disruptive technologies with extraordinary market potential in the life sciences field.

As CEO of Synecor, Mr. Starling is a cofounder of BaroSense, Inc., Bioerodible Vascular Solutions, Inc., (acquired by Guidant/Abbott in April 2004), InnerPulse, Inc. (formerly Interventional Rhythm Management, Inc.), and TransEnterix, Inc., the initial four companies founded and incubated by Synecor. Mr. Starling currently serves as Chairman of the Board for BaroSense, Inc., a Menlo Park, CA - based obesity company, InnerPulse Inc., a RTP, NC - based cardiac rhythm management company, and CEO of TransEnterix, Inc., a RTP, NC - based less invasive GI Surgery company.

William N. Starling received his BS degree from the University of North Carolina at Chapel Hill and his MBA degree from the University of Southern California. He began his 29 year career in the medical technology device industry at American Edwards Laboratories (Edwards LifeSciences). He was subsequently part of the founding management team and Director of Marketing for Advanced Cardiovascular Systems, Inc. (acquired by Guidant/Abbott), and was a cofounder, Vice President and Board member of Ventritex, Inc. (acquired by St. Jude Medical). In 1992, Mr. Starling was a cofounder and Chairman of the Board of Directors and President/CEO of Cardiac Pathways Corporation (acquired by Boston Scientific Corporation), and was responsible for raising significant capital from the early venture capital period through an initial public offering in 1996.

Mr. Starling has been primarily responsible for raising over $275 million in private and public capital for the companies that he has co-founded and the combined revenues of these companies exceeds $1 billion annually. In addition to the companies that he has co-founded, Mr. Starling has made private investments in the initial equity financings of over 40 startup companies and has served/is a Board member in over 20 early stage life science companies. Mr. Starling also serves as an independent, outside Director of AMI-Semiconductor, Inc. (NASDAQ:AMIS), a key vendor for InnerPulse, Inc.

Mr. Starling serves on the Kenan-Flagler Business School's Board of Visitors at the University of North Carolina at Chapel Hill and the External Advisory Board of the Stanford Stroke Center at the Stanford University Medical Center.

top

Michael Williams

Prior to joining SyneCor, LLC as Chief Technology Officer Michael Williams worked as the Vice President of Science and Technology at Medtronic AVE. In this role Williams led the research and development of multiple new technology frontiers including vascular brachytherapy, controlled release drug delivery, photodynamic therapy, gene therapy and neurovascular interventions. Williams founded and was the VP and General Manager of the Neurovascular Technologies Division of Medtronic AVE that was responsible for bringing to market the worlds first neurovascular stent and delivery system. While at Medtronic Williams was also responsible for all of the vascular divisions pre-clinical, biological and materials research.

Before joining AVE Williams held senior management and engineering positions at Microvena Corporation, Guidant's Advanced Cardiovascular Systems and Baxter Healthcare's Pharmaseal Division.

Educated at California Polytechnic State University, San Luis Obispo Williams holds nearly 20 patents, has coauthored 6 technical papers and abstracts and has been an invited speaker at various technical and clinical conferences.

top